Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience
Sathathone Douangprachanh, Hyun Jin Joo, Hyeong Min Park, Nayoung Han, Hye Young Jang, Young Hwan Koh, Tae Hyun Kim, Sung-Sik Han, Sang-Jae Park, Woo Jin Lee, Sang Myung Woo, Jung Won Chun
Korean J Intern Med. 2022;37(6):1216-1222. Published online 2022 Nov 1 DOI: https://doi.org/10.3904/kjim.2022.100
Citations to this article as recorded by 
Advances in Drug Therapy for Pancreatic Neuroendocrine Tumor
文 邱
Journal of Clinical Personalized Medicine.2025; 04(05): 1. CrossRef
Tumor-derived apolipoprotein E confers resistance to temozolomide in pancreatic neuroendocrine tumors
Xin Lou, Yihua Shi, Yi Qin, Wuhu Zhang, Zeng Ye, Fei Wang, Yan Wang, Tian Ding, Desheng Jing, Guixiong Fan, Yue Zhang, Xuemin Chen, Xiaowu Xu, Xianjun Yu, Shunrong Ji, Junfeng Xu
Cell Death & Disease.2025;[Epub] CrossRef
Gastroenteropancreatic neuroendocrine tumors in children and adolescents
Ülkü Miray Yıldırım, Dilşad Koca, Rejin Kebudi
The Turkish Journal of Pediatrics.2024; 66(3): 332. CrossRef